- Home
- HR vs NUVL Comparison
HR vs NUVL Comparison
Compare HR & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HR
- NUVL
- Stock Information
- Founded
- HR 1992
- NUVL 2017
- Country
- HR United States
- NUVL United States
- Employees
- HR N/A
- NUVL N/A
- Industry
- HR Real Estate Investment Trusts
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- HR Real Estate
- NUVL Health Care
- Exchange
- HR Nasdaq
- NUVL Nasdaq
- Market Cap
- HR 5.3B
- NUVL 5.8B
- IPO Year
- HR 1993
- NUVL 2021
- Fundamental
- Price
- HR $16.68
- NUVL $78.24
- Analyst Decision
- HR Hold
- NUVL Strong Buy
- Analyst Count
- HR 5
- NUVL 10
- Target Price
- HR $16.40
- NUVL $119.60
- AVG Volume (30 Days)
- HR 3.6M
- NUVL 497.2K
- Earning Date
- HR 07-31-2025
- NUVL 08-07-2025
- Dividend Yield
- HR 5.76%
- NUVL N/A
- EPS Growth
- HR N/A
- NUVL N/A
- EPS
- HR N/A
- NUVL N/A
- Revenue
- HR $1,222,259,000.00
- NUVL N/A
- Revenue This Year
- HR N/A
- NUVL N/A
- Revenue Next Year
- HR $1.90
- NUVL N/A
- P/E Ratio
- HR N/A
- NUVL N/A
- Revenue Growth
- HR N/A
- NUVL N/A
- 52 Week Low
- HR $14.09
- NUVL $55.54
- 52 Week High
- HR $18.90
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- HR 58.12
- NUVL 49.70
- Support Level
- HR $15.29
- NUVL $71.13
- Resistance Level
- HR $17.07
- NUVL $80.15
- Average True Range (ATR)
- HR 0.41
- NUVL 3.18
- MACD
- HR 0.01
- NUVL -0.41
- Stochastic Oscillator
- HR 78.09
- NUVL 57.50
About HR Healthcare Realty Trust Incorporated
Healthcare Realty Trust Inc is a healthcare facility real estate investment trust. The company focuses on owning, leasing, and managing outpatient facilities and other healthcare properties. The company works to invest in outpatient facilities that are integral to a hospital's operations. It generates all of its revenue in the United States.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.